Position in IMMP
as of Mar 31, 2026
· filed Apr 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Common Shares in IMMP Over Time
Shares Held
Position Value (USD)
Derivatives in IMMP
reported options exposure · as of Mar 31, 2026CallValue
$21
CallShares
62
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $19,945,542 across 57 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | 108,951 | $13,455,448 | |||
| 2 | ABVX |
Abivax S.A.
|
7,605 | $1,013,442 | |
| 3 | SGMT |
Sagimet Biosciences Inc.
|
109,250 | $844,502 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
5,000 | $663,650 | |
| 5 | JANX |
Janux Therapeutics, Inc.
|
30,850 | $473,856 | |
| 6 | NKTR |
Nektar Therapeutics
|
5,500 | $383,955 | |
| 7 | VERU |
Veru Inc.
|
105,081 | $328,903 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
8,170 | $318,711 |
All Filings in IMMP
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $21 | 62 | Call | Defined | 2026-04-15 | |
| 2025-12-31 | $812 | 284 | Call | Defined | 2026-01-16 | |
| 2025-09-30 | $383 | 219 | Call | Defined | 2025-12-15 | |
| 2025-09-30 | $59,711 | 34,121 | Shares | Defined | 2025-12-15 | |
| 2025-06-30 | $31,071 | 18,946 | Shares | Defined | 2025-07-30 | |
| 2025-06-30 | $132 | 81 | Call | Defined | 2025-07-30 | |
| No filing history on record for this holder in this stock. | ||||||